Genmab — December 2014

[Solsen]

...næste behandling

[investor1989]

spændende hvad FDA siger. om de mener det er pengene værd

[Solsen]

Det er lige det. Med mindre Neutopenia udgør et større problem end jeg er i stand til at bedømme må det vel være et "ja"

[120281]

Men vel også først imorgen der er potentiale for lækkerier.

[Solsen]

Denne bliver slået stort op ... Patients who received carfilzomib had a progression-free survival of 26.3 months, as compared with 17.6 months (P = .0001) for those who were treated with lenalidomide and dexamethasone

[Solsen]

http://www.medscape.com/viewarticle/836077?src=wnl_edit_cfna&uac=223854SK Link til Medscape

[Solsen]

Although median overall survival was not reached in either group in this interim analysis, there was a trend toward longer overall survival in the group who received carfilzomib (73.3% vs 65%; HR = 0.79; P=.018). However, the results did not cross the prespecified statistical boundary set by the statisticians when the trial s

[Solsen]

However, the results did not cross the prespecified statistical boundary set by the statisticians when the trial started (P = .005).

[Solsen]

The overall response rates for the two groups was 87.4% in the carfilzomib group, compared with 66.9% in the control arm, and a complete response or better was achieved by 31.8% vs 9.4%.

[Solsen]

På orr og specielt cr er dara bedre. Men hvorvidt forbedringen i pfs kan påvises må tiden vise. Men pæne tal for konkurrenten her.

[Solsen]

http://finance.yahoo.com/news/amgen-onyx-announce-detailed-results-160000281.html Et link alle kan komme på. Se specielt safety 7-8% døde under eller lige efter behandling.

[gentogen]

Serious adverse reactions were reported in 45 percent of patients.

[Solsen]

En helt aktuel info direkte fra ASH siger, at Dara er voldsomt eksponeret på Janssens stand .... Dejligt !

[gentogen]

Forskellen i maintenance pfs er lidt større end tidligere udmeldt

[gentogen]

Og ja. Lyder godt

[Budweis]

ecancer

ecancer

(ecancer.org)

[Budweis]

Prof Mateos speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.

[investor1989]

Siger hun til sidst at 100% af patienterne med Pomalyst respondere på behandling. Altså100% ORR ?

[investor1989]

Nej det hun siger er vidst at frontline patienterne i studiet responderer 100% og 50% af patienterne med pomalyst (R/R patienter)

[investor1989]

Her er en lille Amgen video http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1995470